ArticleLeukemia2004
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
Article in Leukemia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 117 citations in OpenAlex.
- The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia.Annals of hematology · 2026Article
- A Novel NRAS Variant Near the Splice Junction in Moroccan Childhood Acute Lymphoblastic Leukemia: A Molecular Dynamics Study.Biochemical genetics · 2025Article
- Next-generation sequencing reveals clinical features and prognosis of gene mutations in Chinese children with T-cell acute lymphoblastic leukaemia.Frontiers in oncology · 2025Article
- A rare case of pediatric T-cell acute lymphoblastic leukemia with myeloid mimicry.Discover oncology · 2024Article
- Comprehensive genetic analyses of childhood acute leukemia in Iraq using next-generation sequencing.Translational pediatrics · 2023Article
- Spectrum and clinical features of gene mutations in Chinese pediatric acute lymphoblastic leukemia.BMC pediatrics · 2023Article
- Notch Partners in the Long Journey of T-ALL Pathogenesis.International journal of molecular sciences · 2023Review
- Small molecular inhibitors for KRAS-mutant cancers.Frontiers in immunology · 2023Review
- Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects.Blood cancer journal · 2022Article
- Detection ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Genetic and Epigenetic Characterization of a DiscordantInternational journal of molecular sciences · 2021Article
- Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.Nature communications · 2021Article
- An updated account on molecular heterogeneity of acute leukemia.American journal of blood research · 2021Review
- T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?Blood advances · 2020Review
- Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.Frontiers in pediatrics · 2020Article
- Anti-leukemic effects of simvastatin on NRASMolecular biology reports · 2019Article
- Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.Cancer medicine · 2019Article
- Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia.Nature communications · 2019Article
- Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.Haematologica · 2019Article
- Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
Activating mutations in the RAS oncogenes are among the most common genetic alterations in human cancers, including patients with acute lymphoblastic leukemia (ALL). We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy. Leukemic blast DNA from 870 children was analyzed for the presence of activating mutations in the N- or K-RAS oncogenes using a sensitive mutation detection algorithm. RAS mutations were present in the blasts of 131 (15.1%) pediatric ALL patients. The spectrum of mutations included 81 (9.3%) mutations of codons 12/13 of N-RAS, 12 (1.4%) mutations of codon 61 of N-RAS, 39 (4.5%) mutations of codons 12/13 of K-RAS, and 2 (0.2%) mutations of codon 61 of K-RAS. The presence of N- or K-RAS mutations was not associated with white blood cell count at diagnosis, sex, race, extramedullary testicular involvement, central nervous system disease, or NCI/CTEP ALL Risk Group. Patients with an exon 1 K-RAS mutation (codons 12/13) were significantly younger at diagnosis (P=0.001) and less frequently B-lineage phenotype (P=0.01). RAS mutation status did not predict overall survival, event-free survival and disease-free survival. While N- and K-RAS mutations can be identified in 15% of children with newly diagnosed ALL, they do not represent a significant risk factor for outcome using contemporary chemotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.